Whitehawk Therapeutics (WHWK) Non-Current Debt (2021)
Whitehawk Therapeutics' (WHWK) quarterly Non-Current Debt came in at $5.8 million in Q4 2021, little changed on a QoQ basis from $5.8 million in Q3 2021.
Whitehawk Therapeutics (WHWK) Non-Current Debt (2021) Analysis & Trends
Whitehawk Therapeutics (WHWK) has 1 years of Non-Current Debt data on file, last reported at $5.8 million in Q4 2021.
- On a quarterly basis, Non-Current Debt changed N/A year-over-year to $5.8 million in Q4 2021; TTM through Dec 2021 was $5.8 million, a N/A change from a year earlier, with the FY2021 full-year figure at $5.8 million, changed N/A from the prior year.
- Non-Current Debt for Q4 2021 stood at $5.8 million, roughly flat from $5.8 million in the prior quarter.
- Over the last five years, Non-Current Debt for WHWK reached as high as $5.8 million in Q3 2021 and fell as low as $5.8 million in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 105.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 842.92 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.99 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Whitehawk Therapeutics | 34.18 Mn | 34.18 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 5.76 Mn |
| Sep 30, 2021 | 5.76 Mn |